

Phase I Study of DMOT4039A, an Antibody - Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Colin D. Weekes, Laetitia E. Lamberts, Mitesh J. Borad, et al.

Mol Cancer Ther 2016;15:439-447. Published OnlineFirst January 28, 2016.

Updated version Access the most recent version of this article at:
doi:[10.1158/1535-7163.MCT-15-0693](https://doi.org/10.1158/1535-7163.MCT-15-0693)

Cited articles This article cites 29 articles, 12 of which you can access for free at:
<http://mct.aacrjournals.org/content/15/3/439.full#ref-list-1>

Citing articles This article has been cited by 5 HighWire-hosted articles. Access the articles at:
<http://mct.aacrjournals.org/content/15/3/439.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/15/3/439>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.